Combining a new immune therapy with radiation for head and neck cancer
Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma
This study is looking at a new treatment called CB101, which is given directly into tumors along with radiation therapy, to help improve outcomes for patients with advanced head and neck cancer who have few good options left.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curebiotech, INC. NIH-funded |
| Lab location | 1 site (Philadelphia, UNITED STATES) |
| Project ID | NIH-10545347 on NIH RePORTER |
What this research studies
This research investigates the use of a novel immune therapy called CB101 in combination with radiation therapy for patients suffering from head and neck squamous cell carcinoma (HNSCC). The approach involves delivering CB101 directly into tumors to enhance the immune response while minimizing systemic side effects. The study aims to improve treatment outcomes for patients with advanced or relapsed HNSCC, which currently has limited effective treatment options. By utilizing a controlled release formulation of CB101, the research seeks to provide a more effective and localized treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with locoregionally advanced or relapsed head and neck squamous cell carcinoma who have not responded well to standard treatments.
Not a fit: Patients with early-stage head and neck cancer or those who have not yet undergone any treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with advanced head and neck cancer.
How similar studies have performed: While immunotherapy approaches have been explored, the specific combination of CB101 with radiation therapy represents a novel strategy that has shown promising results in preclinical models.
Where this research is happening
Philadelphia, UNITED STATES
- Curebiotech, INC. — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schure, Louis I — Curebiotech, INC.
- Study coordinator: Schure, Louis I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.